Bioventus appoints new head of IR

Aug 27, 2021
Dave Crawford brings two decades of experience to new role

Bioventus, a global leader in innovations for active healing, has appointed Dave Crawford as its vice president of investor relations and treasurer.

Crawford’s new role is an important one as Bioventus has an entirely new set of investors, analysts and potential investors to communicate with. The company listed on Nasdaq via an IPO in February 2021.  

Additionally, as treasurer, he is primarily responsible for managing relationships with Bioventus’ banking and debt providers and helping provide guidance on the long-term capital structure of the company.

Crawford joins Bioventus from Avanos Medical, a medical technology company focused on delivering clinical medical device solutions, where he served as vice president treasurer, IR and financial planning and analysis for nearly seven years. Avanos Medical was previously known as Halyard Health but rebranded as Avanos Medical in 2018.

In 2007 Crawford joined Kimberly-Clark Corporation. He served as the financial lead for the spin-off Halyard Health (now Avanos Medical) in 2014. He also held financial and treasury roles with Eli Lilly & Company from 2001 to 2006.

‘We are happy to welcome Dave to lead our investor relations department and manage treasury at Bioventus,’ says Greg Anglum, senior vice president and CFO. ‘[His] record of accomplishments, strong relationships within the financial community and career in finance and treasury are a perfect fit for the company.’

Sign up to get stories direct to your inbox
logo-black logo-black